2018
Preclinical Pharmacology in the Rhesus Monkey of CW 1759-50, a New Ultra-short Acting Nondepolarizing Neuromuscular Blocking Agent, Degraded and Antagonized by L-Cysteine.
Savarese JJ, Sunaga H, McGilvra JD, Belmont MR, Murrell MT, Jeannotte E, Cooke FE, Wastila WB, Heerdt PM. Preclinical Pharmacology in the Rhesus Monkey of CW 1759-50, a New Ultra-short Acting Nondepolarizing Neuromuscular Blocking Agent, Degraded and Antagonized by L-Cysteine. Anesthesiology 2018, 129: 970-988. PMID: 30212413, DOI: 10.1097/aln.0000000000002408.Peer-Reviewed Original ResearchConceptsNeuromuscular blocking agentsMean arterial pressureBlocking agentArterial pressureNeuromuscular blockadeHeart rateNew neuromuscular blocking agentRhesus monkeysNondepolarizing neuromuscular blocking agentDuration of actionStudy of bolusCirculatory effectsPreclinical pharmacologyControl infusionInstitutional Animal CareED95Large dosesSpontaneous recoveryGantacuriumDose ratioL-cysteineInfusionBolusUse CommitteeRecovery interval
2016
Preclinical Pharmacology of CW002
Sunaga H, Savarese JJ, McGilvra JD, Heerdt PM, Belmont MR, Van Ornum SG, Murrell MT, Malhotra JK, Savard PM, Jeannotte E, Petty BJ, Allen E, Carnathan GW. Preclinical Pharmacology of CW002. Anesthesiology 2016, 125: 732-743. PMID: 27466033, DOI: 10.1097/aln.0000000000001254.Peer-Reviewed Original ResearchMean arterial pressureNeuromuscular blockadeArterial pressureNondepolarizing neuromuscular blocking agentDose ratioSympathetic autonomic responsesNeuromuscular blocking agentsNeuromuscular blocking propertiesRecovery intervalIncrease of HRSympathetic inhibitionBolus dosesCirculatory effectsPreclinical pharmacologyTwitch inhibitionBlocking agentStudy of safetyInstitutional Animal CareAnesthetized monkeysHeart rateSpontaneous recoveryED95CW002Autonomic responsesRapid reversal